A prospective study demonstrating improved visualization when capsule endoscopy is performed after preparation with polyethylene glycol and ascorbic acid by Mascarenhas Saraiva, M
Title:
A prospective study demonstrating improved visualization
when capsule endoscopy is performed after preparation
with polyethylene glycol and ascorbic acid
Authors:
Miguel Mascarenhas Saraiva, Miguel Mascarenhas Saraiva
DOI: 10.17235/reed.2020.6806/2019
Link: PubMed (Epub ahead of print)
Please cite this article as:
Mascarenhas Saraiva Miguel, Mascarenhas Saraiva Miguel.
A prospective study demonstrating improved visualization
when capsule endoscopy is performed after preparation
with polyethylene glycol and ascorbic acid . Rev Esp Enferm
Dig 2020. doi: 10.17235/reed.2020.6806/2019.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form.
Please note that during the production process errors may be discovered which could affect the
content, and all legal disclaimers that apply to the journal pertain.
OR 6806
A case-control study demonstrating improved visualization when capsule endoscopy is
performed after preparation with polyethylene glycol and ascorbic acid
Mascarenhas-Saraiva, Miguel José; Mascarenhas-Saraiva, Miguel
ManopH Gastroenterology Clinic. CUF Hospital. Porto. Portugal.
Contact Information: Miguel Mascarenhas-Saraiva, ManopH, CUF Hospital, Porto (Portugal).
e-mail: miguelmascarenhassaraiva@gmail.com;
ABSTRACT
Background: Capsule endoscopy is used increasingly to obtain images of the gastrointestinal
tract, yet it still remains unclear what is the best preparation for this type of exploration.
Aims: The aim of this study was to compare the results of capsule endoscopy explorations
performed after a basic preparation with a clear liquid diet, reduced iron intake and fasting
or following preparation with a PEG/ascorbate solution.
Methods: The results obtained from a prospective intervention group that used a
PEG/ascorbate solution to prepare for capsule endoscopy were compared with those from a
retrospective group of patients who followed the more basic preparation. The quality of
visualization was assessed with the Park score, assessing visualization of the mucosal
surface and the cleanliness of the intestinal lumen. The capsule transit time in different
segments of the gastrointestinal tract was also evaluated.
Results: A significant improvement in the quality of small intestine visualization was
observed in individuals prepared with the PEG/ascorbate solution as opposed to the basic
preparation. Indeed, there were significant differences in the two separate components that
contribute to the overall visualization score, with better mucosa visualization and lumen
content scores in the intervention group, reflecting improved performance. The presence of
diabetes appears to affect the results of these explorations, at least when employing the
PEG/ascorbate preparation.
Conclusions: Preparation with a PEG/ascorbate solution improves the results of capsule
endoscopy when compared to a basic preparation, without the inconvenience of the more
stringent preparations used for colonoscopies.
Keywords: Capsule Endoscopy, PEG/ascorbate, Bowel preparation, Mucosa visualization,
Gastric transit
Abbreviations: CE, Capsule endoscopy; PEG, polyethylene glycol; CLS, cleansing score; S.D.,
standard deviation; OBG, obscure gastrointestinal bleeding; GI, gastrointestinal.
INTRODUCTION
Capsule endoscopy (CE) is a procedure used to study conditions that mainly affect the small
intestine. However, the use of CE generally produces much better image quality in the
proximal small intestine than in the distal ileum, which is mainly due to the presence of
residual material, such as air bubbles, food residues and bile pigments in the latter (1). Less
frequently, the battery life of the capsule may also become an issue as it may be insufficient
for the capsule to reach the cecum if the transit time becomes too long.
There remains some controversy as to the ideal preparation necessary to perform CE, with
some favoring a less aggressive approach while others recommend more stringent
preparations, such as those used for colonoscopies (2–5). The usual preparation for CE
involves ceasing oral iron supplementation over the preceding 3 days, light meals and a
liquid diet on the day prior to intervention, as well as fasting for the 10 hours prior to
performing CE on the day of examination. However, other bowel preparations have also
been tested, such as those involving the intake of solutions of polyethylene glycol (PEG:
(6–9), alone or in conjunction with ascorbate (10), sodium phosphate (11–15) or magnesium
citrate. The effect of the use of simethicone is controversial, although a combination of PEG
and simethicone has been proposed as a good approach to small bowel preparation for CE
(16). Prokinetics, have also been considered as another option, although this approach is
not generally recommended (16,17).
In order to shed further light on this issue, the aim of this study was to evaluate the
potential benefits of a simple and reliable cleansing regimen that involves the use of a PEG
and ascorbate preparation. The main measures used to evaluate the effectiveness of this
preparation were CE image quality and transit time, while other parameters such as the
completion rate and the quality of mucosa visualization were also assessed.
METHODS
Study design
In order to optimize resources and minimize patient inconvenience, we used here a group of
patients recruited retrospectively as a control for a comparative analysis, with patients
recruited prospectively who prepared for a CE procedure using a PEG/ascorbate protocol. As
such, this was a non-randomized study onto which patients with various clinical indications
that required CE were enrolled, in the case of the control group after the exploration took
place, or before the study took place in the case of the PEG/ascorbate (intervention) group.
The patients in the control group were prepared for CE using a basic protocol that involved
following a diet of light meals and then of clear liquid, reduced iron intake due to the
suspension of iron supplementation for 3 days prior to the procedure when necessary, and
10 hour fasting prior to the exploration. By contrast, the patients in the intervention group
were prepared following a similar protocol but with the additional consumption of 2 liters of
a PEG/ascorbic acid solution. All patients recruited prospectively provided their informed
consent (or that of their legal guardians) to participate in this study, which was carried out
in accordance with the guidelines laid down in the Helsinki declaration and with the
approval of the hospital’s local ethical committee.
Participants
The patients that participated in this study were referred to undergo a CE for a variety of
clinical indications between May 2016 and May 2017. The procedures were carried out at
the Manoph and iCUF centers, and all the subjects were aged between 17 and 83 years of
age (mean age=55 years old; SD=±17), 43 % of patients were male (n=49) and 57 % were
female (n=64; table 1). As described previously, the participants were considered in two
groups: the intervention group (prospective) and the control group (retrospective). The
intervention group included patients who were referred for only one examination. The
exclusion criteria included non-compliance with the prescribed preparation, making it
impossible to follow the protocol, and the use of a different model of capsule from the one
established (see below).
Patients in the intervention group drank one liter of a PEG/ascorbic acid solution the
evening prior to the CE intervention and another liter the morning before ingesting the
capsule. The preparation used is a colon preparation commercialized as Moviprep®, a lemon
flavored powder provided as 4 sachets: 2 sachets “A”, each containing PEG (referred to as
Macrogol; 100 g), anhydrous sodium sulfate (7.5 g), sodium chloride (2.7 g) and potassium
chloride (1 g); and 2 sachets “B”, each containing ascorbic acid (4.7 g) and sodium ascorbate
(5.9 g). The product is prepared by diluting one sachet “A” and one sachet “B” in one liter of
water, as indicated in the package leaflet of the product.
All CE examinations were carried out using the Given SB3 CE system. In the absence of a
more universally accepted standard, small-intestine cleanliness was assessed in accordance
with a scale devised previously by Park et al (1). This scale contemplates a cleansing score
(CLS) of 0 to 3, where 3 is better and 0 is worse. This scoring system selects one frame taken
every 5 min (1 frame/5 min) to reduce the time over which small intestine cleansing is
graded and it evaluates two independent parameters: the proportion of the mucosa
visualized; and the degree of obscuration by bubbles, debris, bile or other material. Small
intestine cleanliness may also be graded objectively by scoring the images according to the
percentage of the area visible. As a rule, the accepted cut-off score for adequate small
intestine preparation for CE is 2.25, defined as the mean of the two individual cleansing
parameters. In addition, when complete small intestine visualization was possible, gastric,
orocecal and small intestine transit times were also compared.
Outcomes
The main evaluation parameters were the quality of visualization of the mucosal surface, as
well as the presence of material in the intestinal lumen, measured as indicated above (1). In
addition, the time required for the capsule to reach the cecum was assessed, considered to
indicate complete transit through the gastrointestinal (GI) tract and a complete exploration.
In addition, the differences in capsule transit time in different GI tract segments were also
evaluated.
Statistical analysis
The results of bowel preparation were compared using a Mann-Whitney U-test, having first
established the data followed a normal distribution using a Kolmogorov-Smirnov test.
Categorical data were compared using a Chi-squared test, and the Fisher-exact and Student
T-tests were also employed where appropriate. P-values less than 0.05 were considered
statistically significant and all statistical analyses were carried out with the SPSS software
(IBM Corp.).
RESULTS
This study analyzed data obtained from 113 CEs carried out on 113 patients, 57 explorations
carried out on patients in the intervention group and 56 in the control group. Various
medical conditions led to the need to perform a CE exploration and they included: obscure
gastrointestinal bleeding (OBG, 51 %), suspicion of Crohn’s disease (20 %), abdominal pain
(11 %), diarrhea (6 %), suspicion of small bowel tumors (5 %), Crohn’s disease follow-up
(4 %) familial polyposis follow-up (2 %), and other less common reasons (2 % - Table 1).
When considering other relevant morbidities in the patient cohort, 13 % of patients had
diabetes, 5 % were obese, 11 % had previously been subjected to digestive system surgery,
35 % had been subjected to abdominal surgery not involving the digestive system and 1 %
had undergone radiotherapy. These characteristics of the patient cohort and the specific
features of the control and intervention group can be seen in Table 1. When these two
study groups were compared, the only statistically significant difference between the two
was related to the proportion of diabetic patients, who constituted 21 % of the intervention
group (n=12) and only 5 % of the control group (n=3, p = 0.014). In addition, the difference
in digestive system surgery undergone by patients in the two groups was close to
significance, with 5 % of the intervention group (n=3) having undergone such surgery, as
opposed to 16 % (n=9) of the control group (p = 0.062). No other relevant differences were
observed between the two groups of patients. When the specific baseline characteristics of
the control and intervention group of the diabetic patients were compared, no significant
differences were observed (Supplementary Table 1).
Efficacy analysis
The main parameters of the exploration that were evaluated were the proportion of cases
in which visualization of the cecum was achieved (a complete examination) and the quality
of the images of the small bowel obtained. In 92 % of explorations it was possible to view
the small intestine in its entirety and conversely, in only 8 % of cases there was no
visualization of the last part of the small bowel and of the entrance of the colon (Table 2).
The median score for visualization of the small bowel was 2.40, which could be broken
down into the visualization of the mucosa, with a median score of 2.70, and the presence of
material in the intestinal lumen that gave a median score of 2.20. The mean gastric transit
time (GTT) was 25 minutes and 7 seconds, while the mean small bowel transit time (SBTT)
was 4 hours and 19 minutes.
When the results of cecum visualization were compared between the two groups, there
were no significant differences in the overall score obtained for the control and intervention
group (5 % vs 11 %, p = 0.321: Table 2). However, significant differences were detected in
the scores for the quality of small bowel visualization (2.45 vs 2.35, p = 0.003: see Figure 1
and Table 2). In the cases where the exploration was considered to be incomplete (with no
cecum visualization), the quality of small bowel visualization was scored as 2.20, and there
was no significant difference between the intervention (2.35) and control group (2.00, p =
0.298: Table 2). Relative to the control group (2.35), a significantly higher score was
apparent for this parameter in the intervention group when the exploration was considered
to be complete (2.45, p = 0.007). Significant differences were also noted when the two
individual parameters that made up the total quality score were evaluated independently,
with a higher mucosa visualization score (2.70 vs 2.60, p = 0.004) and lumen content score
in the intervention group (2.30 vs 2.10, p = 0.003), representing improved performance. In
terms of gastric transit time, the difference between the intervention group (27’02’’) and
the control groups (16’48’’) was close to statistical significance (p = 0.060), while no
significant differences were found in the median CBTT and CE battery life (Table 2).
Confounding adjustment analysis
Since the incidence of diabetes differed between the two study groups (80  % of the diabetic
patients were in the intervention group, n=12), a confounding adjustment analysis was
carried out for this variable (Table 2). Regarding the parameters of the exploration
considered, there were no significant differences in cecum visualization between the
intervention group and the control group of patients with or without diabetes (Table 2). The
capsule reached the cecum in all patients with diabetes in which the exploration was
performed, while in only 93 % of patients without diabetes did the capsule fully pass
through the entire small bowel. While the proportion of these latter patients in which the
exploration was concluded completely appeared to be higher in the intervention group than
in the control group (93 % vs. 89 %), this difference was not statistically significant (p =
0.501).
There were significant differences in the quality of small bowel visualization in the patients
without diabetes, in which the median quality of visualization score was higher in the
intervention group (2.45) than in the control group (2.35, p = 0.010). Segmenting these
patients relative to the completeness of the exploration, the median score in the
intervention group was higher than in the control group (2.50 vs. 2.35 with cecum
visualization, and 2.35 vs. 2.00 with no cecum visualization). Nonetheless, this difference
was only statistically significant in those patients in whom the capsule reached the cecum (p
= 0.021). In diabetic patients, this tendency was also notable and again, the patients in the
intervention group apparently achieved a higher quality of visualization score (2.50) than
those in the control group (2.25), although this did not reach statistical significance probably
due to the small sample size (p = 0.082). A similar trend was consistently observed for the
two individual parameters that made up the overall quality of visualization score
(proportion of the mucosa visualized and lumen content). The GTT and SBTT were not
significantly different between the intervention and control groups, both among patients
with and without diabetes (Table 2).
Completeness cofactors analysis
Bearing in mind that completing the exploration in its entirety is an important factor when
validating the examination, as analysis was carried out to compare the two groups:
uncomplete and complete explorations. The characteristics of these two groups were
similar at baseline (Table 3) but as expected, there were differences in the quality of
visualization with lower scores associated with the incomplete examinations (2.20) rather
than the complete ones (2.45, p = 0.019). There were also differences in the scores obtained
for the individual parameters of quality, with a lower score for the visualization of the
mucosa (2.50: p = 0.031) and for lumen content (1.90, p = 0.014), and higher scores for the
complete explorations (2.70 and 2.20, respectively: see Table 3). By contrast, there were no
differences in GTT between these two groups.
DISCUSSION
In this study we have assessed how a preparative protocol involving the use of a
PEG/ascorbate solution might improve the quality of the results obtained in CE explorations.
When compared to a more basic protocol based on fasting, the preparation with the
PEG/ascorbate solution produced markedly better results in all the main parameters
assessed, visualization and cleansing, as well as a possible improvement in transit time.
These results confirm previous suggestions that the use of PEG solutions combined with
other components may improve the success rates and the clinical information obtained
from CE examinations
Several studies have been published regarding the effectiveness of different bowel
preparations for CE explorations. In 2010, an initial pioneering study of bowel preparation
with PEG was carried out on a sample of 68 patients considered for CE who received either 2
or 4 liters of a PEG solution (1). As a result, it became clear that image quality improved
when patients were prepared for CE using PEG than in those who followed a protocol that
essentially involved fasting alone (18). Indeed, when compared to no bowel preparation,
bowel preparation with PEG results in adequate visualization in significantly more patients
subject to CE. Subsequently, evidence was presented that supported the use of a PEG
solution in conjunction with oral simethicone as the preparation of choice for CE (19), and it
was later proposed that the PEG/simethicone combination might be the best preparation
for small bowel CE (20).
Although it has become clear that patient preparation with PEG is associated with better
visualization of the intestine, as can be measured using the scoring system defined in Park et
al (1), a consensus regarding the need for intestinal preparation for CE is still lacking (2, 21).
Similarly, the stringency of such preparations has yet to be defined. Hence, in this study we
assessed the use of a smaller volume of a PEG solution for bowel preparation, which might
be more convenient and comfortable for the patient, while still providing optimal
visualization of the small intestine. The use of a relatively small volume PEG/ascorbate
preparative solution led to higher quality small intestine visualization, producing better
scores in both of the individual components that made up that score, the quality of mucosa
visualization and lumen content. Similarly, there appeared to be a close to significant
improvement in GTT in these patients. This latter parameter may not only reduce patient
discomfort by shortening the explorations but perhaps, and importantly, it will reduce the
possibility of incomplete explorations due to the loss of battery power during the
intervention.
Defining the least stressful protocol for the patient to prepare for a CE endoscopy is likely to
lead to greater compliance and therefore, produce better results. Indeed, compliance with a
PEG/ascorbate protocol proved to be better than when PEG was combined with
simethicone, the former preparation apparently producing less nausea and vomiting (22).
This higher compliance is likely to lead to a more optimal success rate in terms of the
completion of such explorations and as such, enhance the rate of correct diagnosis while
reducing the need for repeat tests. Both these factors will not only enhance patient
satisfaction but they are also likely to reduce healthcare costs, not least by achieving more
accurate and earlier diagnosis of GI conditions, which are therefore likely to be resolved
more easily and rapidly. It is also important to note that better visualization scores were
associated with completion of the explorations, even though this parameter did not appear
to be associated with any difference in the transit times. Thus, when assessing the benefits
of new protocols it will be important to ensure that they do not have a negative effect on
the proportion of complete explorations.
Although diagnostic yield was not determined here, according to the guidelines for bowel
preparation by the Korean Gut Image Study Group (23) bowel preparation with PEG is
thought to enhance diagnostic yield when compared with fasting alone or a clear liquid diet,
as well as improving small bowel visualization quality, without affecting the cecal
completion rate. Furthermore, previous studies have shown that bowel preparation with a 2
litre PEG solution results in similar diagnostic yield, small bowel visualization quality and
cecal completion rate in CE as that achieved after preparation with a 4 litre PEG solution
(24,25).
In our study, the only significant difference between the baseline characteristics of the
intervention and control group that might have affected the results was a higher proportion
of diabetic patients in the intervention group. However, when the data obtained was
considered in relation to diabetes, the median quality of small bowel visualization was still
higher in the intervention group. As such, diabetes does not appear to explain the
differences observed in the total sample between the control and intervention groups, nor
does it appear to have a negative effect on the results of the explorations, although in this
case the small sample size may potentially have masked any effects of diabetes. Thus, it
would appear not to be necessary to have to adapt the protocol specifically to patients with
diabetes, and perhaps other morbidities.
In summary, this study confirms that low volume PEG preparations represent a good way to
obtain high quality images of the small intestine through CE. However, more studies using
these protocols will still be necessary to confirm these results and to explore further
adaptations that may provide additional advantages to patients.
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Table 1. Baseline characteristics of the patient cohort
All patients
Intervention Control p value Total
group group
Patients, n (%) 57 (50) 56 (50) - 113 (100)
Age, mean (SD) 53 (18) 57 (16) 0.214* 55 (17)
Gender, n (%)
male 27 (47) 22 (39)
0.386+
49 (43)
female 30 (53) 34 (61) 64 (57)
Indication, n (%)
OGB 28 (49) 29 (52) 0.777+ 57 (51)
Abdominal pain 4 (7) 8 (14) 0.210+ 12 (11)
Diarrhea 3 (5) 4 (7) 0.716- 7 (6)
Crohn’s disease 11 (19) 11 (20) 0.963+ 22 (20)
Crohn’s disease
surveillance 3 (5) 2 (4) 1.000
- 5 (4)
Polyposis syndrome
surveillance 2 (4) 0 (0) - 2 (2)
Suspected Tumor 4 (7) 2 (4) 0.679- 6 (5)
Other 2 (4) 0 (0) - 2 (2)
Diabetes, n (%) 12 (21) 3 (5) 0.014+ 15 (13)
Obese, n (%) 5 (9) 1 (2) 0.206- 6 (5)
Prior abdominal surgery, n
(%) 3 (5) 9 (16) 0.062
+ 12 (11)
Prior, non-digestive,
abdominal surgery, n (%) 19 (33) 20 (36) 0.790
+ 39 (35)
Radiotherapy, n (%) 1 (2) 0 (0) 1.000- 1 (1)
*Student T-test, 2 independent samples; +Chi-squared; -Fisher’s exact test; OGB,
obscure gastrointestinal bleeding.
Supplementary table 1. Baseline characteristics of the Diabetic Patients
Diabetic patients
Intervention group Control group p value
Patients, n (%) 12 (80) 3 (20) -
Age, mean (SD) 64 (13) 66 (8) 0.790*
Gender, n (%)
male 4 (33) 1 (33)
1.000-
female 8 (67) 2 (67)
Indication, n (%)
OGB 10 (83) 3 (100)
1.000-
-
Abdominal pain 1 (8) 0 (0)
Diarrhea 0 (0) 0 (0)
Crohn’s disease 0 (0) 0 (0)
Crohn’s disease surveillance 0 (0) 0 (0)
Polyposis syndrome surveillance 0 (0) 0 (0)
Suspected Tumor 1 (8) 0 (0)
Other 0 (0) 0 (0)
Diabetes, n (%)
Obese, n (%) 2 (17) 0 (0) 1.000-
Prior abdominal surgery, n (%) 0 (0) 0 (0) -
Prior, non-digestive, abdominal
surgery, n (%) 3 (25) 1 (33) 0.976
+
Radiotherapy, n (%) 0 (0) 0 (0) -
*Student T-test, 2 independent samples; + Chi-squared; -Fisher’s exact test; OGB,
obscure gastrointestinal bleeding.
Table 2. Results of the exploration in the whole cohort, as well as in diabetic and non-diabetic patients





















Cecum visualization, n (%)
Yes 54 (95) 50 (89) 0.321- 12 (100) 3 (100) 1.000- 42 (93) 47 (89) 0.501-
104 (92)






















































































































































*Student T-test, 2 independent samples; -Fisher’s exact test; #Mann-Whitney U-test; GTT, Gastric transit time; SB, small bowel; CE, Capsule endoscopy.









Patients, n (%) 9 (8) 104 (92) 113 (100)
Interventional 3 (33) 54 (52)
0.321-
57 (50)
Control 6 (67) 50 (48) 56 (50)
Age, mean (SD) 53 (20) 55 (17) 0.214* 55 (17)
Gender, n (%)
male 4 (44) 45 (43)
1.000-
49 (43)
female 5 (56) 59 (57) 64 (57)
Indication, n (%)
OGB 2 (22) 55 (53) 0.094- 57 (51)
Abdominal pain 2 (22) 10 (10) 0.244- 12 (11)
Diarrhea 0 (0) 7 (7) 1.000- 7 (6)
Crohn’s disease 4 (44) 18 (17) 0.070- 22 (20)
Crohn’s disease
surveillance 1 (11) 4 (4) 0.345 5 (4)
Polyposis syndrome
surveillance 0 (0) 2 (2) 1.000
- 2 (2)
Suspected Tumor 0(0) 6 (6) 1.000- 6 (5)
Other 0 (0) 2 (2) 1.000- 2 (2)
Diabetes, n (%) 0 (0) 15 (14) 0.605- 15 (13)
Obese, n (%) 1 (11) 5 (5) 0.399- 6 (5)
Prior abdominal surgery, n (%) 1 (11) 11 (11) 0.271- 12 (11)
Prior, non-digestive, abdominal
surgery, n (%) 5 (56) 34 (33) 0.271
- 39 (35)
Radiotherapy, n (%) 0 (0) 1 (1) 1.000- 1 (1)






























*Student T-test, 2 independent samples; -Fisher’s exact test; #Mann-Whitney U-test; OGB,
obscure gastrointestinal bleeding; GTT, Gastric transit time.

